3 results
To investigate the clinical efficacy in detecting clinically relevant arritmia's (especially AF) of the Reveal XT in patients with mild to moderate heart failure and elevated risk factor for stroke and TIA (CHADS score), currelently not treated…
Primary objective:To assess the long term safety and tolerability of GIVINOSTAT in patients with DMD following core protocols program and with naïve GIVINOSTAT DMD subjects , i.e. subjects screened in study DSC/14/2357/48 who met:- all the inclusion…
Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…